NCT02245308

Brief Summary

The goal of this research study is to examine the effects of a treatment for helping homeless veterans who smoke to stop smoking. Participants in the study will be assigned to one of two study groups. Participants in the first group will be referred to the local Department of Veterans Affairs Medical Center's Smoking Cessation Clinic for treatment. Second group participants will receive a behavioral treatment designed to reward smokers for quitting and staying quit. These participants will also receive telephone counseling and medications for smoking cessation.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
133

participants targeted

Target at P50-P75 for phase_4

Timeline
Completed

Started Oct 2014

Longer than P75 for phase_4

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

September 11, 2014

Completed
8 days until next milestone

First Posted

Study publicly available on registry

September 19, 2014

Completed
12 days until next milestone

Study Start

First participant enrolled

October 1, 2014

Completed
3.5 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 30, 2018

Completed
6 months until next milestone

Study Completion

Last participant's last visit for all outcomes

September 28, 2018

Completed
5 months until next milestone

Results Posted

Study results publicly available

March 7, 2019

Completed
Last Updated

January 4, 2022

Status Verified

December 1, 2021

Enrollment Period

3.5 years

First QC Date

September 11, 2014

Results QC Date

February 6, 2019

Last Update Submit

December 10, 2021

Conditions

Keywords

Tobacco use cessationHomelessnessVeterans

Outcome Measures

Primary Outcomes (1)

  • Number of Participants Self-reported and Bioverified Abstinent From Smoking

    Smoking abstinence at six months will be measured by self-report and bio-verified by salivary cotinine (a by-product of nicotine found in saliva).

    6 months

Secondary Outcomes (1)

  • Intervention Delivery Costs

    6 months

Study Arms (2)

ART

EXPERIMENTAL

Participants assigned to this treatment arm will receive a tele-health intervention that combines guideline-based cognitive-behavioral counseling for smoking cessation, a tele-medicine clinic for access to smoking cessation aids, and an intensive behavioral therapy for smoking cessation called mobile contingency management.

Drug: Nicotine PatchesBehavioral: mobile contingency management (mCM)Behavioral: Smoking cessation counselingDrug: Nicotine rescue methodDrug: Bupropion

Control Group

ACTIVE COMPARATOR

Participants assigned to this active control arm will be referred to VA Specialty Smoking Cessation Clinic for standard-of-care treatment, which may include group counseling, individual counseling, self-help materials, and smoking cessation aids.

Drug: Nicotine PatchesBehavioral: Smoking cessation counselingDrug: Nicotine rescue methodDrug: Bupropion

Interventions

Nicotine replacement therapy in the form of nicotine patches will be provided to ART group participants beginning on their smoking quit date. Nicotine patches may be provided to control group participants as part of usual care.

Also known as: Nicoderm
ARTControl Group

Mobile contingency management (mCM) is a behavioral intervention designed to provide positive reinforcement for remaining abstinent from smoking. In this intervention, participants are loaned a smart phone equipped with a videocamera and a carbon monoxide (CO) monitor. Participants are trained to upload videos of themselves taking CO readings. Any time a participant uploads a video recording that suggests abstinence (i.e., low CO reading), he/she will be provided a monetary reward.

ART

Smoking cessation counseling is a cognitive-behavioral treatment designed to prepare participants for a quit attempt, and to address relapse when necessary.

ARTControl Group

Nicotine replacement therapy in the form of nicotine gum or lozenges will be provided to ART group participants beginning on their smoking quit date. Nicotine gum or lozenges may be provided to control group participants as part of usual care.

Also known as: Nicorette
ARTControl Group

Bupropion SR may be prescribed to medically eligible ART group participants beginning one week prior to quit date. Bupropion may also be prescribed to control group participants as part of usual care.

Also known as: Zyban, Wellbutrin
ARTControl Group

Eligibility Criteria

Age18 Years - 70 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Veteran
  • Homeless
  • Enrolled in Durham VA Medical Center for medical care
  • Current smoker (at least 10 cigarettes per day)
  • Willing to quit smoking in the next 30 days

You may not qualify if:

  • Active substance dependence other than nicotine
  • Uncontrolled psychotic symptoms
  • Severely impaired hearing or speech (must be able to respond to telephone calls)
  • Lack of interest in receiving telephone care
  • Pregnancy

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Durham VA Medical Center, Durham, NC

Durham, North Carolina, 27705, United States

Location

MeSH Terms

Conditions

Tobacco Use DisorderTobacco Use Cessation

Interventions

Tobacco Use Cessation DevicesNicotineNicotine Chewing GumBupropion

Condition Hierarchy (Ancestors)

Substance-Related DisordersChemically-Induced DisordersMental DisordersHealth BehaviorBehavior

Intervention Hierarchy (Ancestors)

TherapeuticsSolanaceous AlkaloidsAlkaloidsHeterocyclic CompoundsPyridinesHeterocyclic Compounds, 1-RingChewing GumPlant GumsBiopolymersPolymersMacromolecular SubstancesPolysaccharidesCarbohydratesCandyFoodDiet, Food, and NutritionPhysiological PhenomenaFood and BeveragesPropiophenonesKetonesOrganic Chemicals

Results Point of Contact

Title
Angela Kirby
Organization
Durham VA Health Care System

Study Officials

  • Jean C Beckham, PhD

    Durham VA Medical Center, Durham, NC

    PRINCIPAL INVESTIGATOR

Publication Agreements

PI is Sponsor Employee
Yes

Study Design

Study Type
interventional
Phase
phase 4
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
FED
Responsible Party
SPONSOR

Study Record Dates

First Submitted

September 11, 2014

First Posted

September 19, 2014

Study Start

October 1, 2014

Primary Completion

March 30, 2018

Study Completion

September 28, 2018

Last Updated

January 4, 2022

Results First Posted

March 7, 2019

Record last verified: 2021-12

Data Sharing

IPD Sharing
Will not share

Locations